• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声心动图对心脏再同步治疗的超级应答者的特征和长期结局:单中心三级护理中心的“真实世界”经验。

Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre.

机构信息

Department of Cardiology, University Hospital Zurich, Ramistrasse 100, Zürich 8091, Switzerland.

出版信息

Heart. 2011 Oct;97(20):1668-74. doi: 10.1136/heartjnl-2011-300222. Epub 2011 Aug 6.

DOI:10.1136/heartjnl-2011-300222
PMID:21821856
Abstract

BACKGROUND

The individual benefit from cardiac resynchronisation therapy (CRT) varies largely among patients.

AIMS

To compare different definitions of echocardiographic super-response to CRT regarding their ability to predict the incidence of adverse events.

METHODS

Three definitions of super-response to CRT were evaluated in 110 consecutive patients with CRT implantation: (1) an absolute increase in ejection fraction of ≥ 10%; (2) a decrease in left ventricular end-systolic volume of ≥ 30%; and (3) a decrease in left ventricular end-diastolic volume of ≥ 20%. The primary endpoint was a combination of time to death, heart transplantation, ventricular assist device implantation and hospitalisation for heart failure. Secondary endpoints included time to first appropriate implantable cardioverter defibrillator (ICD) discharge during follow-up.

RESULTS

All three definitions of super-response were highly predictive of a reduced risk for reaching the primary combined endpoint (3-year estimators: 64% ± 7% vs 82% ± 7% for ejection fraction ≥ 10%; 63% ± 8% vs 92% ± 5% for end-systolic volume ≥ 30%; and 62% ± 8% vs 94% ± 4% for end-diastolic volume ≥ 20%; all p<0.001). In all three analyses, super-responders had a significantly shorter time from diagnosis of heart failure until the time point of CRT implantation. However, even super-responders, independent of the definition, did experience appropriate ICD discharges during follow-up.

CONCLUSIONS

All three definitions of super-response are highly predictive for a favourable outcome after CRT. However, even patients with pronounced reverse left ventricular remodelling experience appropriate ICD discharges during follow-up.

摘要

背景

心脏再同步治疗(CRT)的个体获益在患者之间差异很大。

目的

比较 CRT 后超声心动图超反应的不同定义在预测不良事件发生率方面的能力。

方法

在 110 例连续接受 CRT 植入的患者中评估了 CRT 后超反应的三种定义:(1)射血分数绝对增加≥10%;(2)左心室收缩末期容积减少≥30%;(3)左心室舒张末期容积减少≥20%。主要终点是死亡、心脏移植、心室辅助装置植入和心力衰竭住院的组合。次要终点包括在随访期间首次适当植入式心律转复除颤器(ICD)放电的时间。

结果

三种超反应定义均高度预测主要复合终点风险降低(3 年估计值:射血分数≥10%组为 64%±7%比 82%±7%;收缩末期容积≥30%组为 63%±8%比 92%±5%;舒张末期容积≥20%组为 62%±8%比 94%±4%;均 p<0.001)。在所有三种分析中,超反应者从心力衰竭诊断到 CRT 植入时间点的时间明显更短。然而,即使是超反应者,无论定义如何,在随访期间仍会经历适当的 ICD 放电。

结论

CRT 后超反应的三种定义均高度预测预后良好。然而,即使是左心室重构明显逆转的患者,在随访期间也会经历适当的 ICD 放电。

相似文献

1
Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre.超声心动图对心脏再同步治疗的超级应答者的特征和长期结局:单中心三级护理中心的“真实世界”经验。
Heart. 2011 Oct;97(20):1668-74. doi: 10.1136/heartjnl-2011-300222. Epub 2011 Aug 6.
2
Long-Term Echocardiographic Outcome in Super-Responders to Cardiac Resynchronization Therapy and the Association With Mortality and Defibrillator Therapy.心脏再同步治疗超反应者的长期超声心动图结局及其与死亡率和除颤治疗的关联。
Am J Cardiol. 2016 Oct 15;118(8):1217-1224. doi: 10.1016/j.amjcard.2016.07.041. Epub 2016 Jul 29.
3
"Real world" experience in Cardiac Resynchronization Therapy at a Swiss Tertiary Care Center.瑞士一家三级护理中心心脏再同步治疗的“真实世界”经验。
Swiss Med Wkly. 2017 Apr 18;147:w14425. doi: 10.4414/smw.2017.14425. eCollection 2017.
4
Comparison of low versus high (>40 mm Hg) pulse pressure to predict the benefit of cardiac resynchronization therapy for heart failure (from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Trial).比较低脉压(<40mmHg)与高脉压(>40mmHg)对预测心力衰竭心脏再同步治疗获益的价值(来自多中心自动除颤器植入试验-心脏再同步治疗试验)。
Am J Cardiol. 2014 Oct 1;114(7):1053-8. doi: 10.1016/j.amjcard.2014.07.014. Epub 2014 Jul 17.
5
Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment.心脏再同步治疗的超级应答者仍然存在室性心律失常的风险,并受益于除颤器治疗。
Eur J Heart Fail. 2014 Oct;16(10):1104-11. doi: 10.1002/ejhf.152. Epub 2014 Aug 19.
6
Echocardiographic markers of dyssynchrony as predictors of super-response to cardiac resynchronisation therapy - a pilot study.心脏再同步治疗超反应预测因素——失同步的超声心动图标志物:一项初步研究
Cardiovasc Ultrasound. 2018 Oct 2;16(1):24. doi: 10.1186/s12947-018-0140-0.
7
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.心脏再同步治疗超级反应的预测因素及其对临床结局的改善:MADIT-CRT(心脏再同步治疗的多中心自动除颤器植入试验)研究。
J Am Coll Cardiol. 2012 Jun 19;59(25):2366-73. doi: 10.1016/j.jacc.2012.01.065.
8
Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.超声心动图预测心脏再同步化治疗后的逆重构及随后的事件。
Circ Cardiovasc Imaging. 2013 Nov;6(6):864-72. doi: 10.1161/CIRCIMAGING.112.000026. Epub 2013 Oct 1.
9
Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.心脏再同步治疗中左心室射血分数的正常化与室性心律失常和临床结局的风险:来自多中心自动除颤器植入试验与心脏再同步治疗(MADIT-CRT)试验的结果。
Circulation. 2014 Dec 23;130(25):2278-86. doi: 10.1161/CIRCULATIONAHA.114.011283. Epub 2014 Oct 9.
10
A metric for evaluating the cardiac response to resynchronization therapy.用于评估心脏对再同步治疗反应的指标。
Am J Cardiol. 2014 Apr 15;113(8):1371-7. doi: 10.1016/j.amjcard.2014.01.410. Epub 2014 Jan 31.

引用本文的文献

1
Long-Term Nonprogression Is a Form of Response to Cardiac Resynchronization Therapy.长期无进展是心脏再同步治疗的一种反应形式。
JACC Adv. 2025 Jul 26;4(8):101909. doi: 10.1016/j.jacadv.2025.101909.
2
Outcomes following cardiac resynchronisation therapy in older people.老年人心脏再同步治疗的结果。
Age Ageing. 2023 Nov 2;52(11). doi: 10.1093/ageing/afad222.
3
Timing of cardiac resynchronization therapy implantation.心脏再同步治疗的植入时机。
Europace. 2023 May 19;25(5). doi: 10.1093/europace/euad059.
4
A Mild Dyssynchronous Contraction Pattern Detected by SPECT Myocardial Perfusion Imaging Predicts Super-Response to Cardiac Resynchronization Therapy.单光子发射计算机断层扫描心肌灌注成像检测到的轻度不同步收缩模式可预测心脏再同步治疗的超反应。
Front Cardiovasc Med. 2022 May 31;9:906467. doi: 10.3389/fcvm.2022.906467. eCollection 2022.
5
Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.心脏淀粉样变患者心脏再同步化治疗后的心血管结局。
ESC Heart Fail. 2022 Feb;9(1):740-750. doi: 10.1002/ehf2.13663. Epub 2021 Nov 3.
6
Role of sCD40L in the prediction of super-response to cardiac resynchronization therapy.sCD40L 在预测心脏再同步治疗超反应中的作用。
An Sist Sanit Navar. 2021 Aug 20;44(2):205-214. doi: 10.23938/ASSN.0947.
7
A Predictive Model for Super-Response to Cardiac Resynchronization Therapy: The QQ-LAE Score.心脏再同步治疗超反应的预测模型:QQ-LAE评分
Cardiol Res Pract. 2020 Aug 28;2020:3856294. doi: 10.1155/2020/3856294. eCollection 2020.
8
Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation.心力衰竭持续时间与左心房内径联合预测心脏再同步治疗植入患者的超强反应和长期预后。
Biomed Res Int. 2019 Jun 24;2019:2983752. doi: 10.1155/2019/2983752. eCollection 2019.
9
Mid-term feasibility and safety of downgrade procedure from defibrillator to pacemaker with cardiac resynchronization therapy.从除颤器降级至心脏再同步治疗起搏器的中期可行性及安全性
Int J Cardiol Heart Vasc. 2018 Dec 29;22:78-81. doi: 10.1016/j.ijcha.2018.12.012. eCollection 2019 Mar.
10
Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function.心脏再同步治疗与植入式心律转复除颤器治疗次数的减少相关,因为它能改善心室功能。
Clin Cardiol. 2018 Jun;41(6):803-808. doi: 10.1002/clc.22958. Epub 2018 Jun 5.